Table 1.
Multivariate Prognostic Analyses of OS and PFS for the Placebo Arm
| Variable | OS | PFS | ||
|---|---|---|---|---|
| Hazard Ratio (95% CI) | P-value | Hazard Ratio (95% CI) | P-value | |
| VeriStrat | ||||
| Poor | 1 | 1 | ||
| Good | 0.67 (0.45–1.01) | 0.05 | 0.56 (0.40–0.80) | 0.001 |
| PS | ||||
| 0,1 | 1 | |||
| 2,3 | 1.77 (1.14–2.76) | 0.01 | ||
| Histology | ||||
| Adenocarcinoma | 1 | |||
| Squamous | 1.71 (1.11–2.63) | 0.015 | ||
| Other | 0.80 (0.45–1.24) | 0.25 | ||
| Weight Loss | ||||
| Less than 5% | 1 | |||
| 5% or more | 2.03 (1.31–3.15) | 0.0015 | ||
| Unknown | 0.60 (0.23–1.56) | 0.29 | ||
| FISH | ||||
| FISH− | 1 | 1 | ||
| FISH+ | 2.23 (1.03–4.83) | 0.04 | 2.01 (1.04–2.23) | 0.04 |
| Unknown | 1.51 (0.84–2.70) | 0.17 | 1.58 (0.93–2.66) | 0.09 |
| Time from diagnosis to randomization | ||||
| ≤ 12 months | 1 | |||
| > 12 months | 0.50 (0.34–0.74) | 0.0005 | ||
| Sex | ||||
| Female | 1 | |||
| Male | 1.52 (1.04–2.23) | 0.03 | ||
Missing items indicate that a variable was not significant and so was not used in the analysis.